AACR Special Conference on Functional and Genomic Precision Medicine in Cancer, Boston (March 11 -13, 2025)

During the plenary session, Dr. Pier Paolo Claudio presented on the clinical application of cancer stem cells in precision oncology.

2024: ASCO Annual Meeting, Chicago (May 31 – June 4)

The ChemoID randomized clinical trial (NCT03949283) results in recurrent platinum-resistant ovarian cancer were presented orally at the 2024 ASCO Gynecologic Cancer plenary session by the Dr. Thomas Herzog, the national PI of this multi-institutional trial.

The main goal of the trial was to determine if chemotherapy regimens guided by the ChemoID functional assay can improve the objective response rate (ORR) in patients with recurrent platinum-resistant EOC when compared to empiric treatment selection. The trial met its primary endpoint at the first predetermined efficacy analysis, which compared the objective response rate (ORR) between treatment groups. Subjects treated with chemotherapies guided by the ChemoID assay had a median ORR (mORR) of 55%, compared to 5% for those treated with physician’s choice chemotherapy (p-value p<0.0001). The secondary endpoint analysis of duration of response (DOR) showed statistically significant differences (p<0.0001) between subjects treated with chemotherapies guided by the ChemoID assay and subjects treated with physician’s choice chemotherapy, with a median duration of response of 8 months and 5.5 months, respectively.

https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5518

https://www.uc.edu/news/articles/2024/05/uc-experts-present-at-asco-2024.html

2024: European Association for Cranio Maxillo Facial Surgery (EACMFS) 27th Congress, Rome, Italy (Sept 17-20, 2024)

At the 2024 EACMFS Congress in Rome, Italy, we presented a series of cases of advanced oral cancer treated with ChemoID-guided therapy. Our presentation was titled “The role of a cancer stem cell assay in guiding chemotherapy treatment for advanced oral cancer.”

• [May 2023] Results from the randomized clinical trial: Standard chemotherapy versus chemotherapy chosen by cancer stem cell chemosensitivity testing in the management of patients with recurrent Glioblastoma Multiforme (GBM)  NCT03632135, have been published in Cell Report Medicine (May 2, 2023). In the randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the median overall survival of patients with rGBM (4.5 months) over physician-chosen chemotherapy.  In the ChemoID assay-guided group, median survival was 12 months (95% CI, 10.8–13.2) with ChemoID assay-guided therapy vs. 7.5 (95% CI, 3.5–11.5) with physician choice (log rank p = 0.009). The ChemoID assay-guided group had a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24–0.81; p = 0.008).

• [April 2022] Presented at the Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA, April 8-12, 2022: Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade glioma (NCT03632135).
• [June 2022] Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, June 3-7, 2022: Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade glioma (NCT03632135).
• [August 2022] Presented at the 2nd Annual Conference on CNS Clinical Trials and Brain Metastasis (Plenary Session – Oral Presentation), Toronto, Canada, August 12-13, 2022: Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade glioma (NCT03632135).
• [October 2022] Presented at the Precision Medicine Therapy for Brain Tumors, CNS annual Meeting, San Francisco, CA, October 8-12, 2022: Our data was presented from the Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade glioma (NCT03632135).
• [November 2022] Presented at the Annual Meeting of the Society of Neuro-Oncology (SNO), Tampa, FL, November 16-20, 2022: A Multi-Institutional Randomized Clinical Trial Comparing Assay-Guided Chemotherapy with Physician-Choice Treatment for Recurrent High-Grade Glioma (NCT03632135).

• [March 2021] Presented at APICON – INDIA Conference (Association of Physicians of India):   Stem Cell Assay and Precision Medicine in the Management of Cancer.

• [November 2020] Presented at Society of Neuro-Oncology Annual meeting 2020: Clinical Relevance of Cancer Stem Cell Cytotoxicity Assay in Guiding Treatment of Glioblastoma. Austin TX.
• [November 2020] Presented at Society of Neuro-Oncology Annual meeting 2020: Initial Analysis of Phase-III Trial – Standard Chemotherapy vs. Chemotherapy Guided by a Cancer Stem Cell Test in Recurrent Glioblastoma (NCT03632135). Austin, TX.

• [November 2019] Presented at Society of Neuro-Oncology Annual meeting 2019: Cancer Stem cell cytotoxicity assay-guided treatment in recurrent glioblastoma and progressive anaplastic glioma. Phoenix, AZ.
• [November 2019] Presented at Society of Neuro-Oncology Annual meeting 2019: Phase-III Trial of Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma (NCT03632135). Phoenix, AZ.
• [May 2019] Expert Brain Cancer Treatment at Allegheny Health Network. www.ahn.org/cancer-institute/brain-cancer/treatment
• [April 2019] Presented at Society of Gynecology Oncology Annual meeting 2019: Evaluation of Cancer Stem Cell Drug Response Assay in the Treatment of Recurrent Ovarian Cancer Patients. Hawaii,HI.
• [April 2019] ChemoID data presented at Fels Cancer Research Institute, Temple University, Philadelphia.
• ​[April 2019] News article: ChemoID® utilizes personalized chemotherapy treatment after testing cells. www.apnews.com/2de414d0ffba4e228a394a91b09e3c85
• [March 2019] ChemoID data presented at Cancer Grand Rounds, UMMC, Jackson MS.
• [March 2019] ChemoID data presented at Cancer Grand Rounds, Louisiana State University, New Orleans.
• [February 2019] Granted CPT Code 0564T by the American Medical Association.

• [December 2018] ChemoID data presented at the Cancer Stem Cell Meeting, Austria Dec 2018.
• [August 2018] Presented at International Cancer Stem Cells Meeting 2018: Prospective Analysis of Cancer Stem Cell Drug Response Assay for Glioblastoma Patients. Cancer Stem Cells Meeting 2018, Case Western, Cleveland OH.
• [June 2018] Presented at ASCO 2018: Prospective analysis of cancer stem cells drug response assay for glioblastoma patients. Chicago, IL.
  [June 2018] ChemoID data presented at School of Medicine, Cancer Grand Rounds, University of Salerno, Italy.
• [June 2018] ChemoID data presented at Society of Neuro-Oncology Annual Meeting, New Orleans 2018.
• [May 2018] ChemoID data presented at Cancer Grand Rounds, Penn State University, Hershey, PA
• [March 2018] News article: New technology is making a difference in the fight against cancer.​ www.pvhomed.com/new-technology-is-making-a-difference-in-the-fight-against-cancer/
• [March 2018] ChemoID data presented at Cancer Grand Rounds, University of Cincinnati, OH.
• [March 2018] ChemoID data presented at the School of Dentistry, Residency Program of Maxillofacial Surgery Grand Rounds, University of Mississippi.

• [October 2017] ChemoID data presented at the 21st Annual Interdisciplinary Conference on Supportive Care, Hospice and Palliative Medicine at MD Anderson.  
• [June 2017]  ChemoID data presented at Cancer Grand Rounds, Toledo University.
• [June 2017] Presented at AACR 2017: Analysis of chemo-predictive assay for targeting cancer stem cells in 41 glioblastoma patients.  Chicago, IL.
• [April 2017] ChemoID data presented at the International Meeting INTHEMA, Naples, Italy.
• [March 2017] ChemoID data presented at the Italian Institute of Technology (ITT) Meeting, Genova, Italy.
• ​[February 2017] News article: Researcher’s goal: Find the best chemo for each patient. www.umc.edu/news/News_Articles/2017/February/Researcher-s-goal–Find-the-best-chemo-for-each-patient.html
• [February 2017] ChemoID data presented at the South Regional Meeting, New Orleans.
• [February 2017] ChemoID data presented at Cancer – 2017: 2nd International Cancer Study & Therapy Conference, Baltimore. 

• [September 2016] Presented at the International Cancer Stem Cell Conference, results of the clinical trials on Glioblastoma, September 20-23, 2016.
• [September 2016] News article: 3 new technologies in the field of cancer treatment. By Kevin McCarthy. ​www.nuemd.com/news/2016/09/22/3-new-technologies-field-cancer-treatment
• [May 2016] ChemoID data presented at CEINGE Institute, Naples, Italy.
• [April 2016]  ChemoID data presented at 23rd International meeting of Head and Neck Academicians, Naples, Italy.
• [April 2016] ChemoID data presented at St. Michele Hospital, Naples, Italy.
• [April 2016] ChemoID data presented at Cancer Ground Rounds, Neuroncology group, University of Mississippi Medical Center, April 28, 2016.
• [Feb 2016] ChemoID data presented at West Virginia University Hospital, Morgantown, WV.

• [December 2015] Presented at CAMC Hospital, Charleston, WV.

• [October 2014] Presented at Mercy Hospital, Baltimore  results  of the ChemoID® clinical trials on brain, lung, and breast cancer.
• [September 2014] Presented at Cancer Grand Rounds at the University of Cincinnati, OH,  results  of the ChemoID® clinical trials on brain, lung, and breast cancer.
• [September 2014] Presented at the University of Mississippi, University Cancer Care Center, results  of the ChemoID® clinical trials on brain, lung, and breast cancer.
• [August 2014] Presented at Case Comprehensive Cancer Center and University Hospitals, Cleveland OH,  results  of the ChemoID® clinical trials on brain, lung, and breast cancer.
• [August 2014] Presented at Taussig Cancer Institute, Cleveland Clinic, results  of the ChemoID® clinical trials on brain, lung, and breast cancer.
• [August 2014] Presented at the International Cancer Stem Cell Conference, August 17-20, 2014, results of the ChemoID® clinical trials on brain, lung, and breast cancer.
• [July 2014] Presented at the 5th International Conference RAHMS: Recent Advances in Health and Medical Sciences in Cyprus, July 5-10, 2014, results of the ChemoID® clinical trials on brain, lung, and breast cancer.
• [June 2014] Presented at ASCO 2014: Novel chemosensitivity assay for targeting cancer stem-like cells in brain tumors. Chicago, IL.
• [June 2014] Presented at AACR 2014: Chemosensitivity assay for targeting cancer stem-like cells in malignant brain tumors. AACR 2014, Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy Conference, Orlando, FL.
• [June 2014] News article: New technology develops better personalized cancer treatments.  www.wvgazettemail.com/news/health/new-technology-develops-better-personalized-cancer-treatments/article_9c2a1775-c04a-5a02-a53c-2396fb8d8f1c.html
• [May 2014]  Presented the ChemoID® clinical trial results on brain cancer at the 2014 Annual ASCO Meeting in Chicago, IL (May 30-June 3, 2014).

• [Oct 2013]  Presented at the 2013 Meeting of the Italian Association of Pathology and Diagnostic Cytopathology (Italian Division of the International Academy of Pathology), in Rome, Italy (26-20 Oct), results of the ChemoID® clinical trial on brain and spine tumors.
• [Oct 2013] Presented at the 2013 Annual Meeting of Neurological Surgeons, in San Francisco, California (Oct 19-23), results of the ChemoID® clinical trial on brain and spine tumors.
• [Sept 2013] Presented at the Brigham Women’s Hospital, Harvard University, Boston results of the ChemoID® clinical trial on solid tumors.
• [August 2013] ChemoID data presented at Medica Superspeciality Hospital, Kolkata, India.
• [August 2013] ChemoID data presented at Saroj Gupta Cancer Center & Research Institute, Kolkata, India.
• [August 2013] ChemoID data presented at TATA Medical Center, Kolkata, India.
• [August 2013] ChemoID data presented at Chittaranjan National Cancer Institute CNCI, Kolkata, India.
• [August 2013] ChemoID data presented at Apollo Gleneagles Hospitals, Kolkata, India.
• [August 2013] ChemoID data presented at HGC Healthcare Global Enterprises, Bangalore, India.
• [June 2013] Presented at ASCO 2013: ChemoID assay for Anaplastic Spinal Ependymoma.  Chicago, IL.
• [June 2013] Presented at ASCO 2013: Chemopredictive assay for patients with primary brain tumors.  Chicago, IL.
• [April 2013] Presented at the 2013 BIO INTERNATIONAL CONVENTION in Chicago, IL (April 21st-25th, 2013).
• [February 2013] Presented at the West Virginia Biotechnology Conference in Charleston, WV.

• [August 2012]  Presented clinical data at the 1st International Symposium on Nanomedicine in Drug Delivery and Cancer Diagnosis (August 16, 17, 2012, University of Delaware, Newark, DE).
• [May 2012]   Presented ChemoID® Assay results at the CNR in Rome, Italy.
• [March 2012]   Received research developmental funds for conducting ChemoID® Assay clinical studies.